This is our second symposium on the future directions of immunoglobulin therapy. While the first symposium explored the mechanisms of action of intravenous immune globulin (IVIG) and its use in various clinical disorders, this symposium has taken a new direction in reviewing the potential therapeutic role of monoclonal antibodies in the treatment of malignancy and autoimmune diseases.
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It has been 16 years since K6hler Despite marked improvement in the survival rate of preterm infants in recent years, infection remains a major problem because of the difficulty in making a rapid and accurate diagnosis and the fact that the neonate is an immunocompromised host. It was not difficult to extrapolate the experience of using IVIG as replacement therapy in patients with primary immune deficiencies to other types of acquired or secondary immunoglobutin deficiencies. The hypogammaglobulinemia of prematurity can be most impressive in very low birth weight premature infants (2) . This group of patients appears to be one that might benefit from immunoglobulin therapy. Thus it was very timely for Drs. Gerald Fischer and Carol Baker to present their experiences with IVIG therapy for neonatal sepsis in the premature infant.
In 1981, Dr. Richard Stiehm's group from the University of California at Los Angeles presented their findings on the oral administration of IVIG in premature infants as a specific modality in the prevention or treatment of enteric infections (3). This work was shortly followed by the observations of Dr. Barnes and co-workers from Australia on the use of human immune serum globulin by the oral route in the treatment of low birth weight infants with rotavirus-associated diarrhea (4). Drs. Warren Strober and Randall Goldblum reviewed the cellular and humoral aspects of mucosal gut immunity, respectively. Drs. Martha Eibl, Robert Yolken, and Peter Tutschka each presented their 3S 0271-9142/90/1100-003S$06.00/0 © 1990 Plenum Publishing Corporation work on the potential therapeutic applications of orally administered immune serum globulin, either as specific therapy of enteric pathogens or as prophylactic regimens in patients undergoing bone marrow transplantation.
As can be seen from the foregoing outline, this symposium takes that first step in moving forward with the concept of immunoglobulin therapy in exploring new potential clinical applications, new potential routes of administration, and, more importantly, the potential applications of monoclonal antibodies and genetically engineered monoclonal antibodies in the treatment of a variety of clinical disorders.
